Navigation Links
Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:12/8/2009

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL). The data were presented in an oral presentation(1) at the 51st Annual Meeting of the American Society of Hematology (ASH) and were selected by the Society for inclusion in its "Best of ASH" session. Blinatumomab is a CD19-specific, T cell-engaging BiTE antibody designed to direct a patient's own T cells against cancer cells inducing a self-destruction process in cancer cells.

A total of 21 patients were treated in a phase 2 clinical trial performed in collaboration with the German Multicenter Study Group on Adult Lymphoblastic Leukemia (GMALL). After having received extensive chemotherapy, all patients had ALL malignant cells persisting in their bone marrow, a disease state referred to as minimal residual disease (MRD). The primary endpoint of the clinical trial was the elimination of these cancer cells to an undetectable level in at least 22% of patients. 80% of the evaluable patients (16 of 20 patients) achieved the primary endpoint, all of them already during the first treatment cycle. The responses appear to be durable, with patients free of relapse for currently up to 15 months.

Overall, blinatumomab was well tolerated. The most common adverse events included lymphopenia, leucopenia, pyrexia and hypoimmunoglobulinemia. One patient had to discontinue treatment due to a fully reversible neurological adverse event, and was therefore not evaluable for response assessment.

"Today, patients with MRD-positive ALL after first line therapy have a very high likeli
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER
2. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
3. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
4. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
5. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
6. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
7. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
8. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
9. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
10. White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
11. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 Luoxis Diagnostics, Inc. , ... (NYSE MKT: AMPE), today announced an upcoming presentation ... the American Academy of Surgical Trauma (AAST) and ... Philadelphia, Pennsylvania that will be ... results from a recently completed five-year prospective clinical ...
(Date:8/18/2014)... Mass. and NAGOYA, Japan ... (NYSE: BSX ) and ASAHI INTECC (Securities ... and Nagoya Stock Exchange) have formalized plans to develop ... joint project focuses on creating a device intended to ... The FFR market is an emerging field in interventional ...
(Date:8/18/2014)... , Aug. 18, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p01597713/Bioseparation-Systems-for-Global-Biopharmaceutical-Markets.html ... into three types: chromatography, membranes/filters and centrifuges. ... increasing and fueling growth of the global ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... Anthem Blue Cross and Blue Shield in ... transparency initiative beyond major metro areas into the ... and everywhere in between can now access Anthem ... cost information for 59 specific medical procedures performed ...
... 2010 STAAR Surgical Company (Nasdaq: STAA ... invasive ophthalmic products, today reported results for the third ... grew 6% to $13.2 million reflecting core product (IOLs ... decrease in defocused product revenue as compared to the ...
Cached Medicine Technology:Anthem Blue Cross Blue Shield Introduces Cost Disclosure Tool Throughout Colorado 2Anthem Blue Cross Blue Shield Introduces Cost Disclosure Tool Throughout Colorado 3STAAR Surgical Reports Continued Double Digit Core Revenue Growth 2STAAR Surgical Reports Continued Double Digit Core Revenue Growth 3STAAR Surgical Reports Continued Double Digit Core Revenue Growth 4STAAR Surgical Reports Continued Double Digit Core Revenue Growth 5STAAR Surgical Reports Continued Double Digit Core Revenue Growth 6STAAR Surgical Reports Continued Double Digit Core Revenue Growth 7STAAR Surgical Reports Continued Double Digit Core Revenue Growth 8STAAR Surgical Reports Continued Double Digit Core Revenue Growth 9STAAR Surgical Reports Continued Double Digit Core Revenue Growth 10STAAR Surgical Reports Continued Double Digit Core Revenue Growth 11STAAR Surgical Reports Continued Double Digit Core Revenue Growth 12STAAR Surgical Reports Continued Double Digit Core Revenue Growth 13STAAR Surgical Reports Continued Double Digit Core Revenue Growth 14STAAR Surgical Reports Continued Double Digit Core Revenue Growth 15STAAR Surgical Reports Continued Double Digit Core Revenue Growth 16STAAR Surgical Reports Continued Double Digit Core Revenue Growth 17
(Date:8/19/2014)... Kentucky Markey Cancer Center researchers will provide a simple, free ... require testing for a genetic mutation. , Gliomas a ... are the most common and deadly form of brain ... brain cancer cases. In some of these cases, patients have ... mutation and patients who have this tend to survive ...
(Date:8/19/2014)... Hartford/VA Scholars Program has selected three geriatric ... provides career development and mentorship for projects that ... veterans, but for all older adults. , The ... physical activity among veterans, transitions from VA nursing ... disorder in older veterans. The Hartford/VA Geriatric Scholars ...
(Date:8/19/2014)... 2014 United Benefit Advisors (UBA), ... is pleased to announce Sihle Insurance Group as ... provides a single solution for insurance, financial services, ... needs. With a focus on commercial and personal ... insurance solutions, and payroll services, they are able ...
(Date:8/19/2014)... Utah (PRWEB) August 19, 2014 ... Solution, published a new guide on compliance and ... Benefits, small businesses want to offer employee health ... insurance is unsustainable. Additionally, there are new advantages ... guaranteed-issue, and lower costs. , The new ...
(Date:8/19/2014)... Respected Dallas Plastic Surgeon ... nationwide to feature one of the most advanced ... UltraShape. UltraShape uses ultrasound waves to selectively breakdown ... , The UltraShape System, by Syneron Medical, is ... targets subcutaneous fat, while keeping the surrounding skin ...
Breaking Medicine News(10 mins):Health News:United Benefit Advisors Welcomes New Partner Firm Sihle Insurance Group 2Health News:United Benefit Advisors Welcomes New Partner Firm Sihle Insurance Group 3Health News:Dallas Plastic Surgeon Dr. Benjamin Bassichis is Among the First to Offer UltraShape for Non-Surgical Liposuction 2Health News:Dallas Plastic Surgeon Dr. Benjamin Bassichis is Among the First to Offer UltraShape for Non-Surgical Liposuction 3
... ... QT Beat-to-Beat(sm) Studies , ... Rochester, N.Y. (PRWEB) March 11, 2010 -- iCardiac Technologies, Inc., a leader in ... pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. iCardiac will provide ...
... ... last three years fundraising to send life-saving bed nets to families in ... grassroots campaign to prevent malaria in Africa, the leading killer of children ... and plans to raise $50,000 by the time he starts college. This ...
... ... Plunge, a benefit for the Special Olympics. , ... Salt Lake City, UT (PRWEB) March 11, 2010 -- Bullfrog International, makers ... Pelican Bay Marina in Saratoga Springs, Utah and hosted by the Saratoga Police Department. Bullfrog ...
... ... from a national workshop have been released to address deep-vein thrombosis (DVT) and pulmonary ... each year. , ... Washington, D.C. (PRWEB) March 11, 2010 -- Three critical recommendations from a national workshop ...
... , WEDNESDAY, March 10 (HealthDay News) -- By analyzing ... U.S. scientists have identified gene mutations associated with the ... the limbs, hands and feet. , The study, published ... of Medicine , involved sequencing the complete genome of ...
... infestations, study shows, , WEDNESDAY, March 10 (HealthDay News)-- ... ivermectin is more effective than the standard treatment, the ... published in the March 11 issue of the ... percent of those treated with ivermectin were lice-free after ...
Cached Medicine News:Health News:Top 10 Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2Health News:High School Student's College Prerequisite: Save Five Thousand Lives in Africa. Teen Supports Nothing But Nets in Malaria Fight 2Health News:High School Student's College Prerequisite: Save Five Thousand Lives in Africa. Teen Supports Nothing But Nets in Malaria Fight 3Health News:Hot Tub Company Helps Swimmers Thaw and Supports Special Olympics 2Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 2Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 3Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 4Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 5Health News:Gene Mutations Identified for Charcot-Marie-Tooth Syndrome 2Health News:For Tough Head Lice, Pill Tops Lotion 2Health News:For Tough Head Lice, Pill Tops Lotion 3
... The Awaya stereo test was developed to ... Awaya Stereo test employs the more reliable ... eye. It is not dependent on polarizing spectacles ... first target is an attractive image of a ...
... is designed to assist patients with red-green color ... filter cuts off wavelengths shorter than 582 nm ... of their most difficult color distinctions. A color ... determine whether a color is in the longer ...
Features a twist-on backswitch, with a diffused, cobalt blue light beam....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
Medicine Products: